The Global Interferon Beta Drugs Market Size accounted for USD 4.0 Billion in 2021 and is estimated to garner a market size of USD 5.5 Billion by 2030 rising at a CAGR of 3.9% from 2022 to 2030. Increasing multiple sclerosis is the primary factor boosting the interferon beta drugs market share during the projected timeframe. Rising R&D in MS drugs is a popular interferon beta drugs market trend that is driving the industry forward. The five major classes of interferon beta drugs that can be administered subcutaneously, intravenously, or intramuscularly are Avonex, Extavia, Betaseron, Plegridy, and Rebif.
Interferon Beta Drugs Market Report Key Highlights
- Global interferon beta drugs market revenue is estimated to reach USD 5.5 Billion by 2030 with a CAGR of 3.9% from 2022 to 2030
- According to the National Multiple Sclerosis Society, over 2.8 million people are living with multiple sclerosis in the world
- North America interferon beta drugs market generated over 40% regional shares in 2021
- An estimated 1 million people live with MS in the United States
- Asia-Pacific interferon beta drugs market will rise with a substantial CAGR from 2022 to 2030
- Based on product type segment, interferon beta-1A evaluated more than 50% of the total market share in 2021
- Growing incidences of MS in the world fuels the interferon beta drug market growth in coming years
The human body naturally forms three forms of interferons including alpha, beta, and gamma that control the activity of the immune system. Moreover, doctors use an artificial or manmade version of these interferons especially beta interferons to treat Multiple Sclerosis (MS). Interferon-beta (IFNβ) medications help to lessen the worsening of the disease and can also stabilize the course of the disease. Additionally, the medication can also slow down the process of having physical disability over time. These can be administered in the body with the procedures like intravenous, subcutaneous, and intramuscular.
Global Interferon Beta Drugs Market Dynamics
Market Drivers
- Rising prevalence of multiple sclerosis
- Increasing research & development activities
- Surging demand of combination therapies
Market Restraints
- Alternative treatment for multiple sclerosis
- Side effects of these drugs
Market Opportunities
- Growing focus on novel drugs development
- Rising regulatory approval for the beta drugs
Interferon Beta Drugs Market Report Coverage
Market |
Interferon Beta Drugs Market |
Interferon Beta Drugs Market Size 2021 |
USD 4 Billion |
Interferon Beta Drugs Market Forecast 2030 |
USD 5.5 Billion |
Interferon Beta Drugs Market CAGR During 2022 - 2030 |
3.9% |
Interferon Beta Drugs Market Analysis Period |
2018 - 2030 |
Interferon Beta Drugs Market Base Year |
2021 |
Interferon Beta Drugs Market Forecast Data |
2022 - 2030 |
Segments Covered |
By Product Type, By Source of Administration, By End-User, And By Geography
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
Key Companies Profiled |
A S Biotech, Apple Pharmaceuticals, Bayer, Biogen Idec., Hoffmann-La Roche Ltd, Merck KGaA, Mili Healthcare, Novartis AG, Pfizer Inc, and Rewine Pharmaceutical. |
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
Interferon Beta Drugs Market Insights
The rising prevalence of multiple sclerosis (MS) across the globe is driving market growth. It’s a disabling disease of the brain and spinal cord (central nervous system), where the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between the brain and the rest of your body. According to several studies, some of the major factors responsible for developing MS include low vitamin D levels in the blood is a risk factor for the development of MS, smoking increases a person’s risk of developing MS, and obesity in childhood and adolescence, particularly in girls, increased the risk of later developing MS. In turn, an increasing number of chain smokers, and obese people are expected to support the demand for interferon beta drugs in the market. Additionally, the potential factors associated with the interferon beta drugs like, it can slow down the worsening of the disease and simultaneously decrease the symptoms, and can be used in combination therapies for the treatment of multiple sclerosis are further bolstering the market growth.
In contrast, the side effects of interferon-beta drugs such as fatigue, sweating, chills, muscle aches, and fever as well as redness, swelling, and pain during the initial treatment procedure are some of the factors likely to limit the growth over the forecast period from 2022 to 2030.
Covid-19 Impact on Interferon Beta Drugs Market
The global pandemic which has got its birth in China has badly affected people across the globe. Countries have announced nationwide lockdowns in order to combat the increasing number of cases of coronavirus. The pharmaceutical industry across the globe has seen major changes owing to the increasing burden of patients with coronavirus. The industry has come under major stress to develop vaccines or effective treatments for people. The major manufacturers in the healthcare sector have been involved in R&D for the development of vaccines. For instance, Synairgen plc has announced in January 2021 that the first patient has been dosed in the UK as a part of a global Phase III trial evaluating the inhaled formulation of interferon beta-1a (SNG001), for the treatment of hospitalized COVID-19 patients.
Interferon Beta Drugs Market Segmentation
The worldwide interferon beta drugs market is split based on product type, source of administration, end-user, and geography.
Interferon Beta Drugs Market By Product Type
- Interferon Beta-1A
- Interferon Beta-1B
- Peginterferon Beta-1A
According to our interferon beta drugs industry analysis, interferon beta-1A accounted for a significant market revenue in 2021. Interferon beta-1a intramuscular injection is used to treat adults with various forms of multiple sclerosis. MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control.
Interferon Beta Drugs Market By Source of Administration
- Intravenous
- Subcutaneous
- Intramuscular
By source of administration segment, intravenous acquired a considerable market share in 2021 and is likely to do so in the coming years. Subcutaneous would generate an impressive market share during the forecast timeframe from 2022 to 2030. However, intramuscular is expected to attain substantial market growth in the coming years.
Interferon Beta Drugs Market By End-User
- Hospitals Pharmacies
- Retail Pharmacies
- Drug Stores Online
- Online Pharmacies
The hospitals' pharmacies sub-segment earned the highest revenue in 2021 and will continue to do so in the future years, according to our interferon beta drugs market forecast. Retail pharmacies are also accounting for a significant share from 2022 to 2030. On the other hand, online pharmacies are likely to attain the fastest growth rate in the coming future.
Interferon Beta Drugs Market Regional Outlook
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
The Middle East & Africa (MEA)
- Gulf Cooperation Council (GCC)
- South Africa
- Rest of the Middle East & Africa
North America is leading the interferon beta drugs market with maximum revenue share
In 2021, the region is gaining potential growth owing to the presence of major players and authorized organizations (FDA) in the region. The 5 types of interferon beta got approval in the US market by the FDA, which include Interferon Beta-1A (Avonex, Rebif), interferon beta-1b (Betaseron, Extavia), and peginterferon beta-1a (Plegridy). Avonex can be taken once a week as a shot into the muscle. The people who start taking it at an early stage of multiple sclerosis may be able to go longer before any physical disabilities begin or get worse. Rebif is taken three times a week as a shot under the skin. Betaseron and Extavia are taken as a shot that goes just under the skin every other day. Additionally, pleurisy can be taken a shot just under the skin every 2 weeks as it lasts longer in the body. The early presence of these interferon beta drugs in the region is primarily contributing to its dominating share in the market.
Interferon Beta Drugs Market Players
The interferon beta drugs companies profiled in the report include A S Biotech, Apple Pharmaceuticals, Bayer, Biogen Idec., Hoffmann-La Roche Ltd, Merck KGaA, Mili Healthcare, Novartis AG, Pfizer Inc, and Rewine Pharmaceutical among others.
CHAPTER 1. Industry Overview of Interferon Beta Drugs Market
1.1. Definition and Scope
1.1.1. Definition of Interferon Beta Drugs
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Interferon Beta Drugs Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Interferon Beta Drugs Market By Product Type
1.2.3. Interferon Beta Drugs Market By Source of Administration
1.2.4. Interferon Beta Drugs Market By End-User
1.2.5. Interferon Beta Drugs Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Interferon Beta Drugs Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Interferon Beta Drugs Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2021
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2021
4.2. R&D Status of Major Manufacturers in 2021
CHAPTER 5. Interferon Beta Drugs Market By Product Type
5.1. Introduction
5.2. Interferon Beta Drugs Revenue By Product Type
5.2.1. Interferon Beta Drugs Revenue (USD Billion) and Forecast, By Product Type, 2018-2030
5.2.2. Interferon Beta-1A
5.2.2.1. Interferon Beta-1A Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.3. Interferon Beta-1B
5.2.3.1. Interferon Beta-1B Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.4. Peginterferon Beta-1A
5.2.4.1. Peginterferon Beta-1A Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 6. Interferon Beta Drugs Market By Source of Administration
6.1. Introduction
6.2. Interferon Beta Drugs Revenue By Source of Administration
6.2.1. Interferon Beta Drugs Revenue (USD Billion) and Forecast, By Source of Administration, 2018-2030
6.2.2. Intravenous
6.2.2.1. Intravenous Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
6.2.3. Subcutaneous
6.2.3.1. Subcutaneous Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
6.2.4. Intramuscular
6.2.4.1. Intramuscular Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 7. Interferon Beta Drugs Market By End-User
7.1. Introduction
7.2. Interferon Beta Drugs Revenue By End-User
7.2.1. Interferon Beta Drugs Revenue (USD Billion) and Forecast, By End-User, 2018-2030
7.2.2. Hospitals Pharmacies
7.2.2.1. Hospitals Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
7.2.3. Retail Pharmacies
7.2.3.1. Retail Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
7.2.4. Drug Stores
7.2.4.1. Drug Stores Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
7.2.5. Online Pharmacies
7.2.5.1. Online Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 8. North America Interferon Beta Drugs Market By Country
8.1. North America Interferon Beta Drugs Market Overview
8.2. U.S.
8.2.1. U.S. Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
8.2.2. U.S. Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
8.2.3. U.S. Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
8.3. Canada
8.3.1. Canada Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
8.3.2. Canada Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
8.3.3. Canada Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
8.4. North America PEST Analysis
CHAPTER 9. Europe Interferon Beta Drugs Market By Country
9.1. Europe Interferon Beta Drugs Market Overview
9.2. U.K.
9.2.1. U.K. Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
9.2.2. U.K. Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
9.2.3. U.K. Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
9.3. Germany
9.3.1. Germany Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
9.3.2. Germany Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
9.3.3. Germany Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
9.4. France
9.4.1. France Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
9.4.2. France Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
9.4.3. France Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
9.5. Spain
9.5.1. Spain Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
9.5.2. Spain Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
9.5.3. Spain Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
9.6. Rest of Europe
9.6.1. Rest of Europe Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
9.6.2. Rest of Europe Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
9.6.3. Rest of Europe Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Interferon Beta Drugs Market By Country
10.1. Asia Pacific Interferon Beta Drugs Market Overview
10.2. China
10.2.1. China Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
10.2.2. China Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
10.2.3. China Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
10.3. Japan
10.3.1. Japan Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
10.3.2. Japan Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
10.3.3. Japan Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
10.4. India
10.4.1. India Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
10.4.2. India Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
10.4.3. India Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
10.5. Australia
10.5.1. Australia Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
10.5.2. Australia Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
10.5.3. Australia Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
10.6. South Korea
10.6.1. South Korea Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
10.6.2. South Korea Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
10.6.3. South Korea Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
10.7.2. Rest of Asia-Pacific Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
10.7.3. Rest of Asia-Pacific Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Interferon Beta Drugs Market By Country
11.1. Latin America Interferon Beta Drugs Market Overview
11.2. Brazil
11.2.1. Brazil Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
11.2.2. Brazil Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
11.2.3. Brazil Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
11.3. Mexico
11.3.1. Mexico Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
11.3.2. Mexico Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
11.3.3. Mexico Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
11.4. Rest of Latin America
11.4.1. Rest of Latin America Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
11.4.2. Rest of Latin America Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
11.4.3. Rest of Latin America Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Interferon Beta Drugs Market By Country
12.1. Middle East & Africa Interferon Beta Drugs Market Overview
12.2. GCC
12.2.1. GCC Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
12.2.2. GCC Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
12.2.3. GCC Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
12.3. South Africa
12.3.1. South Africa Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
12.3.2. South Africa Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
12.3.3. South Africa Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Interferon Beta Drugs Revenue (USD Billion) and Forecast By Product Type, 2018-2030
12.4.2. Rest of Middle East & Africa Interferon Beta Drugs Revenue (USD Billion) and Forecast By Source of Administration, 2018-2030
12.4.3. Rest of Middle East & Africa Interferon Beta Drugs Revenue (USD Billion) and Forecast By End-User, 2018-2030
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. Player Analysis Of Interferon Beta Drugs Market
13.1. Interferon Beta Drugs Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Interferon Beta Drugs Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. Company Profile
14.1. A S Biotech
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (USD Billion), 2021
14.1.3.2. A S Biotech 2021 Interferon Beta Drugs Business Regional Distribution
14.1.4. Product /Service and Specification
14.1.5. Recent Developments & Business Strategy
14.2. Apple Pharmaceuticals
14.3. Bayer
14.4. Biogen Idec.
14.5. Hoffmann-La Roche Ltd
14.6. Merck KGaA
14.7. Mili Healthcare
14.8. Novartis AG
14.9. Pfizer Inc
14.10. Rewine Pharmaceutical